RBC Capital raised the firm’s price target on CVS Health (CVS) to $93 from $81 and keeps an Outperform rating on the shares. The company reported a solid Q3 EPS beat with Medical Benefit Ratio comfortably below expectations after adjusting for prior-period one-time items and trend in the non-continuing ACA exchange business, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health Stock Feels the Heat as $5.7B Write-Down Weighs on ‘Record’ Q3
- CVS Health’s Strategic Growth and Financial Resilience Underpin Buy Rating
- CVS Health Reports Record Revenue Despite Impairment
- CVS Health Earnings Call Highlights Robust Growth and Strategic Adjustments
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!